



Vivo Biosciences Inc.

Accelerating Preclinical Research, Drug Discovery & Therapeutics

NEWS RELEASE

Vivo Biosciences Exhibits at the 2009 International BIO Convention

Birmingham, AL – May 25, 2009 – Vivo Bioscience attended the recent 2009 International BIO gathering of cutting edge pharmaceutical and biotechnology executives in the industry. Attendance as an exhibitor allowed Vivo to showcase its defining 3D HuBiogel™ Assay platform technology to the drug discovery industry. Although attendance was down approximately 20 – 30% at the conference as a whole, Vivo enjoyed a nice flow of traffic through its booth with expression of interest from a variety of international as well as United States' based companies and institutions. Dr. Raj Singh, President and Chief Executive Officer of Vivo Biosciences stated, "This is an excellent forum to highlight the merits of our HuBiogel™-based drug discovery platform to the pharma and biotech companies of the world. Our assay platform provides a physiologically relevant and predictive in vitro assay suite that will save drug development companies time and money." Vivo Biosciences exhibition booth was located in the India Pavilion. Dr. Lee T. Martin, Senior Director, Business Development, commented, "The decision makers are here, and they are expressing interest in the capabilities of Vivo's in vitro oncology therapeutic discovery platform. Additional interest is being expressed about our potential in the stem cell arena and oncology personalized medicine field." Vivo Biosciences is looking forward to the next 2010 International BIO convention being held in Chicago, IL on May 3rd – 6th at the McCormick Place Convention Center.

About Vivo Biosciences, Inc.

Vivo Biosciences, Inc. is an emerging, venture-backed biotechnology company, incorporated in 2004 for the purpose of introducing a novel, human biomatrix, HuBiogel™, to the biological research markets. VBI strives to maximize the functional relevance & predictability of your cell-based assays. We are confident that our unique HuBiogel™ assays will improve drug efficacy/ toxicity endpoints and critical preclinical decisions.

About the HuBiogel™ Assay Platform

The 3D HuBiogel™ Assay Platform is a novel in vitro assay platform that recapitulates human cells in a fully human extracellular matrix. These three dimensional systems provide the drug development industry with a cost efficient assay to identify drug efficacy and toxicity. Current systems use animal based or synthetic extracellular matrices which may impact their in vivo predictability.

Vivo Biosciences' Contact: Lee T. Martin, Ph.D.

Source: Vivo Biosciences, Inc.

Vivo Biosciences Website: www.vivobiotech.com